These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 14625662)
1. 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases. Garcia JR; Simo M; Perez G; Soler M; Lopez S; Setoain X; Lomeña F Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1714. PubMed ID: 14625662 [No Abstract] [Full Text] [Related]
2. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027 [TBL] [Abstract][Full Text] [Related]
3. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175 [TBL] [Abstract][Full Text] [Related]
4. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262 [TBL] [Abstract][Full Text] [Related]
5. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy? Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049 [TBL] [Abstract][Full Text] [Related]
6. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Ak I; Sivrikoz MC; Entok E; Vardareli E Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Qiu ZL; Xue YL; Song HJ; Luo QY Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353 [TBL] [Abstract][Full Text] [Related]
8. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases? Sahin E; Zincirkeser S; Akcan AB; Elboga U J BUON; 2014; 19(1):291-6. PubMed ID: 24659678 [TBL] [Abstract][Full Text] [Related]
9. Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomography. Foo SS; Ramdave S; Berlangieri SU; Scott AM Australas Radiol; 2004 Jun; 48(2):214-6. PubMed ID: 15230758 [TBL] [Abstract][Full Text] [Related]
10. A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases. Zhang L; Chen L; Xie Q; Zhang Y; Cheng L; Li H; Wang J BMC Med Imaging; 2015 Mar; 15():7. PubMed ID: 25885599 [TBL] [Abstract][Full Text] [Related]
11. Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG. Tarnawska-Pierścińska M; Hołody Ł; Braziewicz J; Królicki L Nucl Med Rev Cent East Eur; 2011; 14(2):105-8. PubMed ID: 22219151 [TBL] [Abstract][Full Text] [Related]
12. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167 [TBL] [Abstract][Full Text] [Related]
13. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. Cook GJ; Houston S; Rubens R; Maisey MN; Fogelman I J Clin Oncol; 1998 Oct; 16(10):3375-9. PubMed ID: 9779715 [TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography and bone metastases. Fogelman I; Cook G; Israel O; Van der Wall H Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376 [TBL] [Abstract][Full Text] [Related]
16. False negative F-18 FDG PET/CT in nonsmall cell lung cancer bone metastases. An YS; Yoon JK; Lee MH; Joh CW; Yoon SN Clin Nucl Med; 2005 Mar; 30(3):203-4. PubMed ID: 15722832 [No Abstract] [Full Text] [Related]
17. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877 [TBL] [Abstract][Full Text] [Related]
18. Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm. Pezeshk P; Sadow CA; Winalski CS; Lang PK; Ready JE; Carrino JA Acad Radiol; 2006 Aug; 13(8):1011-5. PubMed ID: 16843854 [TBL] [Abstract][Full Text] [Related]
19. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Ohta M; Tokuda Y; Suzuki Y; Kubota M; Makuuchi H; Tajima T; Nasu S; Suzuki Y; Yasuda S; Shohtsu A Nucl Med Commun; 2001 Aug; 22(8):875-9. PubMed ID: 11473206 [TBL] [Abstract][Full Text] [Related]
20. [18F-FDG PET and bone scintigraphy to search for bone metastasis of lung cancer]. Aflalo-Hazan V; Gutman F; Raileanu I; Frétault J; Kerrou K; Grahek D; Montravers F; Talbot JN Rev Pneumol Clin; 2006 Jun; 62(3):164-9. PubMed ID: 16840993 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]